|
tyo:4523
|
6671
|
Apr 14th, 2024 12:00AM
|
Eisai US
|
117K
|
2988
|
Open
|
|
Apr 14th, 2024 06:23AM
|
Apr 14th, 2024 06:23AM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 13th, 2024 12:00AM
|
Eisai US
|
117K
|
2988
|
Open
|
|
Apr 13th, 2024 05:16AM
|
Apr 13th, 2024 05:17PM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 12th, 2024 12:00AM
|
Eisai US
|
117K
|
2986
|
Open
|
|
Apr 12th, 2024 05:30AM
|
Apr 12th, 2024 02:25PM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 11th, 2024 12:00AM
|
Eisai US
|
117K
|
2987
|
Open
|
|
Apr 11th, 2024 07:32AM
|
Apr 11th, 2024 05:12PM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 10th, 2024 12:00AM
|
Eisai US
|
117K
|
2987
|
Open
|
|
Apr 10th, 2024 05:17AM
|
Apr 11th, 2024 12:39AM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 9th, 2024 12:00AM
|
Eisai US
|
117K
|
2986
|
Open
|
|
Apr 9th, 2024 05:41AM
|
Apr 9th, 2024 03:49PM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 8th, 2024 12:00AM
|
Eisai US
|
117K
|
2986
|
Open
|
|
Apr 8th, 2024 06:12AM
|
Apr 8th, 2024 06:12AM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 7th, 2024 12:00AM
|
Eisai US
|
117K
|
2986
|
Open
|
|
Apr 7th, 2024 05:48AM
|
Apr 7th, 2024 09:18PM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 7th, 2024 12:00AM
|
Eisai US
|
117K
|
2985
|
Open
|
|
Apr 7th, 2024 05:48AM
|
Apr 7th, 2024 05:48AM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|
|
tyo:4523
|
6671
|
Apr 6th, 2024 12:00AM
|
Eisai US
|
117K
|
2986
|
Open
|
|
Apr 6th, 2024 05:29AM
|
Apr 6th, 2024 05:29AM
|
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
|
Open
|
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
|
Open
|
200 Metro Blvd.
|
Nutley
|
NJ
|
US
|
07110
|
|
Eisai
|
|
|